The patient was a 76-year-old man. Sorafenib was prescribed for treatment of progressive hepatocellular carcinoma (HCC). Six weeks after starting administration of Sorafenib, he was admitted into our hospital on suspicion of gastrointestinal bleeding because melena and anemia were detected. When upper gastrointestinal endoscopy was carried out, multiple ulcers with a parallel tendency were recognized extending from the superior duodenal angle to the descending part of the duodenum. According to Forrest's classification, the ulcers were grade IIc, and consequently administration of Sorafenib was stopped and conservative management was started. After 1-week hospitalization, upper gastrointestinal endoscopy revealed that the multiple ulcers of the descending part of the duodenum tended to improve promptly. On the other hand, the ulcers of the superior duodenal angle did not improve. This was diagnosed as direct invasion of HCC into that part. Computerized tomography (CT) revealed enlargement of the tumor, and the therapeutic effect of Sorafenib was judged as PD. Later, the patient's liver dysfunction got worse, hepatic failure progressed, and finally he died three months after starting treatment.
In addition to the hand-foot syndrome, Sorafenib may induce thrombosis via inhibition of vascular endothelial growth factor. As adverse reactions of low incidence, Sorafenib reportedly causes gastrointestinal bleeding and perforation, but development of gastrointestinal ulcers is rare. In our present case, multiple ulcers with a parallel tendency developed in the descending part of the duodenum after starting Sorafenib administration, while improvement could be achieved following discontinuation of this medicine. We should consider the possibility of development of multiple ulcers consequent to impairment of the blood flow to the duodenum due to Sorafenib administration. We herein report on this case and discuss the relevant literature.
View full abstract